Stay updated on LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Sign up to get notified when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.

Latest updates to the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now includes a consolidated Locations section listing study sites by state (Alabama, California, Maryland, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania) and updates the revision to v3.3.3; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.9%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.0%

- Check48 days agoChange DetectedRemoved the government funding/status notice from the page, while core study details remain unchanged.SummaryDifference0.3%

- Check63 days agoChange DetectedThere are no significant updates to core study information; observed differences appear to be minor formatting or layout adjustments only. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference2%

- Check98 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.